Welcome to our dedicated page for Hangzhou Tigerme news (Ticker: HNGZY), a resource for investors and traders seeking the latest updates and insights on Hangzhou Tigerme stock.
Hangzhou Tigerme (HNGZY) delivers integrated clinical research solutions for biopharmaceutical and medical device development worldwide. This news hub provides investors and industry professionals with timely updates on regulatory milestones, trial advancements, and strategic initiatives shaping global healthcare innovation.
Access verified updates across key operational areas: earnings reports, clinical trial phases, regulatory submissions, technology partnerships, and international expansions. Our curated news collection simplifies tracking of critical developments in decentralized trial models, data management systems, and cross-border research collaborations.
Bookmark this page for streamlined monitoring of Hangzhou Tigerme’s progress in accelerating medical breakthroughs through compliant, technology-driven clinical solutions. Regular updates ensure you stay informed about developments impacting the company’s position in global pharmaceutical R&D ecosystems.
Tigermed (300347.SZ/3347.HK) reported its 2024 annual results with total revenue of RMB 6,603 million, showing a 10.6% YoY decrease. The company's adjusted net profit declined 42.1% YoY to RMB 855 million. However, net new bookings grew 7.3% YoY to RMB 8,423 million, with backlog reaching RMB 15,776 million (+12.0% YoY).
The company maintained its leading position with 12.8% market share in China's clinical CRO market, assisting in 28 Class I new drug and 6 innovative medical device approvals. Clinical Trial Solutions revenue decreased 23.8% YoY to RMB 3,178 million, while Clinical-related and Lab Services revenue increased 6.5% YoY to RMB 3,425 million.
Notable achievements include expanding global presence through acquisitions in Japan and China, launching AI initiatives, and managing 831 ongoing drug clinical trials. The company operates in 33 countries with 10,185 employees globally, including 1,626 overseas staff.
Hangzhou Tigermed Consulting Co., (300347.SZ / 3347.HK), a leading clinical research solutions provider, reported its 2024 interim results. The company saw a clear quarter-on-quarter improvement in Q2 2024, with total revenue reaching 1,698 million RMB (2.3% increase), gross profit at 705 million RMB (12.2% increase), and net profit attributable to shareholders after deducting extraordinary gain or loss at 337 million RMB (11.3% increase).
For the first half of 2024, Tigermed achieved total revenue of 3,358 million RMB and gross profit of 1,333 million RMB. The company maintained its leading position in China's clinical service market with a 12.8% market share and expanded its global presence across 37 countries. Tigermed's clinical operations in North America, Asia-Pacific, and EMEA regions showed significant growth, with the company handling over 133 multi-region clinical trials.
Hangzhou Tigermed Consulting Co., Ltd. reported its annual results for 2022, highlighting a 35.9% year-over-year revenue growth, totaling RMB 7,085.5 million. Net profit before non-recurring items rose by 25.0% to RMB 1,539.5 million. Clinical Trial Solutions revenue grew by 37.8%, while overseas revenue surged 41.8%. The company achieved a year-end backlog of RMB 13,785.9 million, up 20.9% YoY. Tigermed expanded its global footprint with acquisitions and new operations, establishing a presence in over 50 countries. The launch of innovative digital tools for clinical trials is expected to enhance efficiency and growth moving forward.
Tigermed has successfully completed the acquisition of Marti Farm, a European Contract Research Organization. This strategic move enhances Tigermed's expertise in Europe, allowing for tailored clinical research solutions and improved safety monitoring on a global scale. Marti Farm has a 12-year track record in pharmaceuticals, medical devices, and food supplements, providing invaluable consultancy and regulatory services. Its pharmacovigilance cloud solution is already utilized by over 100 companies. Tigermed aims to leverage Marti Farm's expertise to strengthen its service offerings and expand its global presence in the healthcare sector.
Hangzhou Tigermed Consulting reported strong financial results for the first half of 2022, achieving a 74.8% year-over-year growth in total revenue to RMB 3,594.2 million. The adjusted net profit attributable to owners rose by 26.6% to RMB 876.5 million. The company’s revenue from Clinical Trial Solutions surged by 110.1%, while overseas revenue doubled, increasing by 102.3%. As of June 30, 2022, Tigermed was managing 607 ongoing drug projects, including 207 international ones, and it ranked as the largest clinical service provider in China with a 12.5% market share.
Hangzhou Tigermed Consulting Co., Ltd. reported impressive 2021 annual results, achieving a 63.3% year-over-year revenue growth of RMB 5,213.5 million. The company's adjusted net profit attributable to owners rose by 60.6% to RMB 1,585.3 million. Significant revenue increases were noted in Clinical Trial Solutions (up 97.1%) and overseas markets (up 91.1%). New bookings surged 74.2% YoY, totaling RMB 9,645.5 million. In 2021, Tigermed expanded globally with over 8,300 employees across 52 countries, continuing to innovate in clinical research.
